DK2591114T3 - Immunisering af store pattedyr med lave doser af RNA - Google Patents
Immunisering af store pattedyr med lave doser af RNA Download PDFInfo
- Publication number
- DK2591114T3 DK2591114T3 DK11736497.6T DK11736497T DK2591114T3 DK 2591114 T3 DK2591114 T3 DK 2591114T3 DK 11736497 T DK11736497 T DK 11736497T DK 2591114 T3 DK2591114 T3 DK 2591114T3
- Authority
- DK
- Denmark
- Prior art keywords
- rna
- virus
- liposomes
- immunogen
- use according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/60—Vectors comprising a special origin of replication system from viruses
Claims (13)
1. immunogen-kodende, selvreplikerende RNA til anvendelse i en profylaktisk eller terapeutisk fremgangsmåde til at øge et immunrespons i et stort pattedyr ved ikke-viral fremføring af RNA'et, omfattende: (i) at indgive til pattedyret en dosis af mellem 2pg og lOOpg af det immunogen-kodende RNA, hvor det store pattedyr er et menneske, hest, kvæg, eller gris og RNA'et indgives i kombination med et fremføringssystem omfattende: (i) liposomer; (ii) ikke-toksiske og bionedbrydelige polymermi kroparti kier; og/eller (iii) en kationisk submikrometer-olie-i-vand-emulsion.
2. RNA til anvendelse ifølge krav 1, hvor RNA'et indgives til skeletmuskelvæv.
3. RNA til anvendelse ifølge et hvilket som helst foregående krav, hvor RNA'et indgives ved injektion.
4. RNA til anvendelse ifølge krav 3, hvor injektion er via en nål.
5. RNA til anvendelse ifølge et hvilket som helst foregående krav, hvor RNA'et er +-strenget.
6. RNA til anvendelse ifølge et hvilket som helst foregående krav, hvor RNA'et er en alfavirus-baseret RNA-replikon.
7. RNA til anvendelse ifølge et hvilket som helst foregående krav, hvor RNA-molekylet koder for (i) en RNA-afhængig RNA-polymerase, som kan transskribere RNA fra det selvreplikerende RNA-molekyle og (ii) et immunogen.
8. RNA til anvendelse ifølge krav 7, hvor polymerasen er en alfavirus-replikase.
9. RNA til anvendelse ifølge krav 8, hvor RNA-molekylet ikke koder for alfavirus-strukturproteiner.
10. RNA til anvendelse ifølge et hvilket som helst foregående krav, hvor RNA'et koder for et immunogen, som kan frembringe et immunrespons mod et bakterie, en virus, en svamp eller en parasit.
11. RNA til anvendelse ifølge krav 10, hvor immunogenet kan frembringe et immunrespons in vivo mod (a) respiratorisk syncytialvirus (RSV), såsom RSV-glycoprotein F; (b) orthomyxovirus, såsom influenza A-, B- og C-virus; eller (c) herpesvirus, såsom herpes simplex-viruser (HSV), varicella zoster-virus (VZV), Epstein-barr-virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), og human herpesvirus 8 (HHV8).
12. RNA til anvendelse ifølge et hvilket som helst foregående krav, hvor det store pattedyr er et menneske.
13. Farmaceutisk sammensætning til anvendelse i en fremgangsmåde til immunisering af et menneske, en hest, et kvæg, eller en gris mod en sygdom, omfattende (a) mellem 2 pg og lOOpg af immunogen-kodende, selvreplikerende RNA til non-viral fremføring per dosisenhed og (b) et fremføringssystem omfattende: (i) liposomer; (ii) ikke-toksiske og bionedbrydelige polymermikropartikler; og/eller (iii) en kationisk submikrome-ter-olie-i-vand-emulsion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36179410P | 2010-07-06 | 2010-07-06 | |
PCT/US2011/043096 WO2012006369A2 (en) | 2010-07-06 | 2011-07-06 | Immunisation of large mammals with low doses of rna |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2591114T3 true DK2591114T3 (da) | 2016-08-29 |
Family
ID=44629097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11736497.6T DK2591114T3 (da) | 2010-07-06 | 2011-07-06 | Immunisering af store pattedyr med lave doser af RNA |
Country Status (13)
Country | Link |
---|---|
US (9) | US10487332B2 (da) |
EP (1) | EP2591114B1 (da) |
JP (1) | JP5940064B2 (da) |
CA (2) | CA2804492A1 (da) |
CY (1) | CY1117819T1 (da) |
DK (1) | DK2591114T3 (da) |
ES (1) | ES2586580T3 (da) |
HR (1) | HRP20160805T1 (da) |
HU (1) | HUE029284T2 (da) |
PL (1) | PL2591114T3 (da) |
PT (1) | PT2591114T (da) |
SI (1) | SI2591114T1 (da) |
WO (1) | WO2012006369A2 (da) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3243526T (lt) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Rnr pristatymas, skirtas keleto imuninio atsako paleidimui |
SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
HRP20221522T1 (hr) | 2010-07-06 | 2023-02-17 | Glaxosmithkline Biologicals S.A. | Čestice za dostavljanje nalik virionu za samo-replicirajuće rna molekule |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2923634T3 (es) | 2010-08-31 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Liposomas pequeños para la administración de ARN que codifica para inmunógeno |
SI3970742T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegilirani liposomi za dostavo RNA, ki kodira imunogen |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
KR20200084048A (ko) | 2011-06-08 | 2020-07-09 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
ES2861428T3 (es) | 2011-07-06 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG10201602654SA (en) | 2011-10-03 | 2016-05-30 | Moderna Therapeutics Inc | Modified nucleosides,nucleotides,and nucleic acids,and uses thereof |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
AU2014204826A1 (en) * | 2013-01-10 | 2015-07-09 | Seqirus UK Limited | Influenza virus immunogenic compositions and uses thereof |
AU2014212003C1 (en) | 2013-02-04 | 2020-07-16 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
EP3904502A3 (en) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions and methods |
EP2958588B1 (en) | 2013-02-22 | 2017-08-23 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
TR201903248T4 (tr) | 2013-03-15 | 2019-03-21 | Glaxosmithkline Biologicals Sa | Rna saflaştırma yöntemleri. |
AU2014232370B2 (en) | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
AU2013401479B2 (en) * | 2013-09-26 | 2019-04-04 | BioNTech SE | Particles comprising a shell with RNA |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
RU2722482C2 (ru) | 2013-11-25 | 2020-06-01 | Серес Терапеутикс, Инк. | Синергические бактериальные композиции и способы их получения и применения |
WO2015095241A2 (en) | 2013-12-16 | 2015-06-25 | Seres Health, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
CN106659803A (zh) | 2014-04-23 | 2017-05-10 | 摩登纳特斯有限公司 | 核酸疫苗 |
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
CA3002922A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
RS63381B1 (sr) | 2015-10-22 | 2022-08-31 | Modernatx Inc | Vakcine protiv respiratornih virusa |
SG11201803360UA (en) * | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
KR20180096592A (ko) * | 2015-10-22 | 2018-08-29 | 모더나티엑스, 인크. | 호흡기 세포융합 바이러스 백신 |
MA46023A (fr) * | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de la grippe à large spectre |
JP2018531290A (ja) | 2015-10-22 | 2018-10-25 | モデルナティーエックス, インコーポレイテッド | 性感染症ワクチン |
EP3402549A4 (en) | 2016-01-11 | 2019-09-11 | Verndari, Inc. | MICRO-NEEDLE COMPOSITIONS AND METHODS OF USE THEREOF |
JP2019528312A (ja) * | 2016-08-07 | 2019-10-10 | ノバルティス アーゲー | mRNA媒介性の免疫化方法 |
CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170260A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
TW201907937A (zh) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | 阿爾法病毒新抗原載體 |
KR20200028395A (ko) | 2017-06-15 | 2020-03-16 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
KR20200040277A (ko) | 2017-08-14 | 2020-04-17 | 세레스 테라퓨틱스, 인코포레이티드 | 담즙정체성 질환 치료를 위한 조성물 및 방법 |
WO2019036008A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
CA3087537A1 (en) | 2018-01-04 | 2019-07-11 | Jan-willem THEUNISSEN | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
CN114072516A (zh) | 2019-05-30 | 2022-02-18 | 磨石生物公司 | 经修饰的腺病毒 |
AU2020298267A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Self-replicating RNA molecules for hepatitis B virus (HBV) vaccines and uses thereof |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
US20210347828A1 (en) | 2020-05-11 | 2021-11-11 | Janssen Pharmaceuticals, Inc. | RNA Replicon Encoding a Stabilized Corona Virus Spike Protein |
IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
KR20230164648A (ko) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | SARS-CoV-2 변이체에 대한 RNA 백신 |
EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
US20230172870A1 (en) * | 2021-12-08 | 2023-06-08 | Yale University | Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues |
Family Cites Families (242)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US4853228A (en) | 1987-07-28 | 1989-08-01 | Micro-Pak, Inc. | Method of manufacturing unilamellar lipid vesicles |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
EP0737750B1 (en) | 1989-03-21 | 2003-05-14 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
FR2676072B1 (fr) | 1991-05-03 | 1994-11-18 | Transgene Sa | Vecteur de delivrance d'arn. |
US5693535A (en) | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
US5750390A (en) | 1992-08-26 | 1998-05-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene |
WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
US20020102273A1 (en) | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
EP1624068A1 (en) | 1993-06-01 | 2006-02-08 | Life Technologies Inc. | Genetic immunization with cationic lipids |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
WO1995027721A1 (en) | 1994-04-07 | 1995-10-19 | Akzo Nobel N.V. | Freeze-dried compositions comprising rna |
US5993850A (en) | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5965434A (en) | 1994-12-29 | 1999-10-12 | Wolff; Jon A. | Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
JPH11512609A (ja) | 1995-09-27 | 1999-11-02 | アメリカ合衆国 | クローン化されたヌクレオチド配列からの感染性RSウイルス(respiratory syncytial virus)の生産 |
DE69716240T2 (de) | 1996-02-12 | 2003-06-26 | Ml Lab Plc London | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten |
DE19605548A1 (de) | 1996-02-15 | 1997-09-04 | Boehringer Ingelheim Int | Zusammensetzung für die Transfektion höherer eukaryotischer Zellen |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
CA2259179C (en) | 1996-07-03 | 2008-09-23 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
ES2305157T3 (es) | 1996-09-13 | 2008-11-01 | Lipoxen Technologies Limited | Liposomas. |
US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
US6048546A (en) | 1997-07-31 | 2000-04-11 | Sandia Corporation | Immobilized lipid-bilayer materials |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
NZ504725A (en) * | 1997-11-28 | 2003-02-28 | Crown In The Right Of The Quee | Flavivirus expression and delivery system |
US6009406A (en) | 1997-12-05 | 1999-12-28 | Square D Company | Methodology and computer-based tools for re-engineering a custom-engineered product line |
GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
WO1999055310A1 (en) * | 1998-04-27 | 1999-11-04 | Altus Biologics Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
US6517842B1 (en) | 1998-06-29 | 2003-02-11 | The United States Of America As Represented By The Secretary Of The Army | Marburg virus vaccines |
EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
EP1141313A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
GB9908309D0 (en) | 1999-04-12 | 1999-06-02 | Phares Pharm Res Nv | Lipid aggregate forming compositions and their use |
ES2238799T3 (es) | 1999-09-09 | 2005-09-01 | Curevac Gmbh | Transferencia de arn-m. |
CN1411512A (zh) | 1999-10-20 | 2003-04-16 | 约翰霍普金斯大学医学院 | 嵌合的免疫原性组合物及其编码核酸 |
US8541008B2 (en) | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
US20030212022A1 (en) | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
US7149665B2 (en) | 2000-04-03 | 2006-12-12 | Browzwear International Ltd | System and method for simulation of virtual wear articles on virtual models |
WO2001079253A1 (en) | 2000-04-18 | 2001-10-25 | Human Genome Sciences, Inc. | Extracellular matrix polynucleotides, polypeptides, and antibodies |
WO2001093836A2 (en) | 2000-06-09 | 2001-12-13 | Teni Boulikas | Encapsulation of polynucleotides and drugs into targeted liposomes |
ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
WO2002009645A2 (en) | 2000-08-01 | 2002-02-07 | The Johns Hopkins University | Intercellular transport protein linked to an antigen as a molecular vaccine |
WO2002012281A2 (en) * | 2000-08-03 | 2002-02-14 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
DE60118228T2 (de) | 2000-09-28 | 2006-12-14 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Mikropartikel zur verabreichung von heterologen nukleinsäure |
IL154853A0 (en) | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
WO2002079239A2 (en) | 2001-01-31 | 2002-10-10 | U.S. Army Medical Research Institute Of Infectious Diseases | Chimeric filovirus glycoprotein |
AU2002242016A1 (en) | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
WO2002072027A2 (en) | 2001-03-14 | 2002-09-19 | University Of Alabama Research Foundation | Oncolytic rna replicons |
WO2002074920A2 (en) * | 2001-03-16 | 2002-09-26 | Johns Hopkins University | A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same |
CA2445947A1 (en) | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
US20030077251A1 (en) | 2001-05-23 | 2003-04-24 | Nicolas Escriou | Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
EP2842964A1 (de) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
US20050175629A1 (en) | 2001-08-31 | 2005-08-11 | Giuseppe Del Giudice | Helicobacter pylori vaccination |
DE60233061D1 (de) | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
US20050163832A1 (en) | 2002-02-13 | 2005-07-28 | Vladimir Torchilin | Intracellular delivery of therapeutic agents |
DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
JP4722481B2 (ja) | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
DE60310562T2 (de) | 2002-07-05 | 2007-10-11 | Lipoxen Technologies Ltd. | Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen |
WO2004018506A2 (en) | 2002-08-22 | 2004-03-04 | Cytos Biotechnology Ag | Inducible alphaviral/orip based gene expression system |
BR0314236A (pt) | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
JP4991108B2 (ja) | 2002-12-13 | 2012-08-01 | アルファバックス,インコーポレイティド | 多抗原性アルファウイルス・レプリコン粒子及び方法 |
WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US8338583B2 (en) | 2003-02-04 | 2012-12-25 | Bar-Ilan University | Snornai-small nucleolar RNA degradation by RNA interference in trypanosomatids |
WO2004076645A2 (en) | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
AU2004223477B2 (en) | 2003-03-20 | 2009-03-26 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
EP1637144A4 (en) | 2003-05-30 | 2010-01-13 | Nippon Shinyaku Co Ltd | OLIGONUCLEIC ACID CONTAINING COMPOSITE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
US20100255002A1 (en) | 2003-06-26 | 2010-10-07 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
DK1651666T3 (da) | 2003-07-11 | 2009-08-31 | Alphavax Inc | Alfavirus-baserede cytomegalovirusvacciner |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
WO2005007196A2 (en) | 2003-07-16 | 2005-01-27 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
EP1512393A1 (de) | 2003-09-08 | 2005-03-09 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen |
WO2005046621A2 (en) | 2003-11-12 | 2005-05-26 | The United States Of America As Represented By The Secretary Of The Navy | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
AU2005245956B2 (en) | 2004-05-18 | 2011-05-19 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
CA2566355C (en) | 2004-05-18 | 2014-04-15 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
GB0411428D0 (en) | 2004-05-21 | 2004-06-23 | Got A Gene Ab | Vectors |
EP2811027A1 (en) | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
EP1766035B1 (en) | 2004-06-07 | 2011-12-07 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
WO2005120152A2 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
AU2005327198B2 (en) | 2004-07-09 | 2011-03-31 | University Of North Carolina At Chapel Hill | Viral adjuvants |
WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
JP5086082B2 (ja) | 2004-10-01 | 2012-11-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | C型肝炎ウイルス複製系 |
EP1811960A2 (en) | 2004-11-19 | 2007-08-01 | Novosom AG | Improvements in or relating to pharmaceutical compositions for local administration |
GB2421025A (en) | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
ATE552267T1 (de) | 2005-02-18 | 2012-04-15 | Novartis Vaccines & Diagnostic | Immungene von uropathogenen escherichia coli |
DK1858920T3 (da) | 2005-02-18 | 2016-02-29 | Glaxosmithkline Biolog Sa | Proteiner og nukleinsyrer fra meningitis/sepsis-associeret escherichia coli |
WO2006092607A1 (en) | 2005-03-02 | 2006-09-08 | The Secretary Of State For Defence | Pharmaceutical composition |
GB0504436D0 (en) | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
US20100034822A1 (en) | 2005-03-30 | 2010-02-11 | Vega Masignani | Haemophilus Influenzae Type B |
US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
CN101238146A (zh) | 2005-05-12 | 2008-08-06 | 诺华疫苗和诊断有限公司 | 砂眼衣原体的免疫原性组合物 |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
WO2007014754A1 (en) | 2005-08-02 | 2007-02-08 | I.D.M. Immuno-Designed Molecules | Process for the preparation of liposomal formulations |
US7951384B2 (en) | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
ES2937245T3 (es) | 2005-08-23 | 2023-03-27 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
EP1764089A1 (en) | 2005-09-15 | 2007-03-21 | Novosom AG | Serum stable liposomes comprising amphoter II lipid mixtures |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
BRPI0616687A2 (pt) | 2005-09-29 | 2011-06-28 | Elan Pharm Inc | compostos de pirimidinil amida que inibem a adesão leucocitária mediada por vla-4 |
EP2357000A1 (en) | 2005-10-18 | 2011-08-17 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
JP2007112768A (ja) | 2005-10-24 | 2007-05-10 | Kyoto Univ | 肝指向性リポソーム組成物 |
JP2009515831A (ja) | 2005-10-25 | 2009-04-16 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ペスト菌(Yersiniapestis)抗原を含む組成物 |
EP1969001A2 (en) | 2005-11-22 | 2008-09-17 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and sapovirus antigens |
WO2008051245A2 (en) | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
EP2004141A2 (en) | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
CA2654563A1 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
EP2035581B1 (en) | 2006-06-21 | 2012-09-26 | The Scripps Research Institute | Dna composition against tumor stromal antigen fap and methods of use thereof |
CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
CA2663295C (en) | 2006-09-12 | 2020-03-10 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
US20100015218A1 (en) | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
WO2008109806A2 (en) | 2007-03-08 | 2008-09-12 | Massachusetts Institute Of Technology | Electrostatic coating of particles for drug delivery |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
AP3018A (en) | 2007-03-29 | 2014-10-31 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expressionof a gene from the ebola |
US8748591B2 (en) | 2007-04-17 | 2014-06-10 | The Board Of Regents Of The University Of Texas System | Chimeric sindbis-western equine encephalitis virus and uses thereof |
ES2531520T3 (es) | 2007-05-04 | 2015-03-16 | Marina Biotech, Inc. | Lipoaminoácidos y usos de los mismos |
EP2152890A1 (en) | 2007-05-23 | 2010-02-17 | MannKind Corporation | Multicistronic vectors and methods for their design |
DE102007029471A1 (de) | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
AU2008266807B2 (en) | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
EP2173771A1 (en) | 2007-07-04 | 2010-04-14 | Ribovax Biotechnologies SA | Antibodies against human cytomegalovirus (hcmv) |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
WO2009026328A2 (en) | 2007-08-21 | 2009-02-26 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
WO2009042794A2 (en) | 2007-09-26 | 2009-04-02 | Vanderbilt University | Venezuelan equine encephalitis replicons expressing paramyxovirus glycoproteins as vaccine |
EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
EP2225374B1 (en) | 2007-11-26 | 2013-08-14 | Novartis AG | Methods of generating alphavirus particles |
EP2067749A1 (en) | 2007-11-29 | 2009-06-10 | Total Petrochemicals France | Process for purification of an aqueous phase containing polyaromatics |
WO2009074861A2 (en) | 2007-12-10 | 2009-06-18 | Powderject Research Limited | Improved vaccine |
US20110165223A1 (en) | 2008-01-02 | 2011-07-07 | The Johns Hopkins University | Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen |
EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
US20110110857A1 (en) | 2008-03-06 | 2011-05-12 | Roberto Petracca | Mutant forms of chlamydia htra |
NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
US20100040650A1 (en) | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
EP2130912A1 (en) | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
WO2009156155A1 (en) | 2008-06-25 | 2009-12-30 | Probiogen Ag | Cell line for propagation of highly attenuated alphaviruses |
JP5712126B2 (ja) | 2008-06-25 | 2015-05-07 | ノバルティス アーゲー | 遅延型追加刺激免疫処置に対する迅速な応答 |
BRPI0916443A2 (pt) | 2008-07-16 | 2017-10-31 | Inst Res Biomedicine | anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos |
JP2010025644A (ja) | 2008-07-16 | 2010-02-04 | Kochi Univ Of Technology | 硝酸イオンの呈色試薬並びにこれを用いた硝酸イオンの検出及び定量方法 |
CA2730620A1 (en) | 2008-07-16 | 2010-01-21 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
CA2733147A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | Microparticles for use in immunogenic compositions |
CL2008002322A1 (es) | 2008-08-07 | 2009-06-05 | Univ Concepcion | Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna. |
KR101661746B1 (ko) | 2008-08-13 | 2016-09-30 | 캘리포니아 인스티튜트 오브 테크놀로지 | 캐리어 나노입자, 그리고 관련된 조성물, 방법 및 시스템 |
US20110177122A1 (en) | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
ES2475065T3 (es) | 2008-10-09 | 2014-07-10 | Tekmira Pharmaceuticals Corporation | Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos |
CA3006395C (en) | 2008-11-07 | 2022-05-31 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
KR20220150995A (ko) | 2008-11-10 | 2022-11-11 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
JP6046348B2 (ja) | 2008-11-18 | 2016-12-14 | タケダ ヴァクシーンズ, インコーポレイテッド | Rsvfvlpならびにその製造および使用の方法 |
EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
EP2419129A2 (en) | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions for immunising against staphylococcus aerus |
US20100285112A1 (en) | 2009-05-05 | 2010-11-11 | Tatiana Novobrantseva | Methods of delivering oligonucleotides to immune cells |
KR102205886B1 (ko) | 2009-06-10 | 2021-01-21 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
EP2450031B1 (en) | 2009-07-02 | 2018-08-29 | Konica Minolta Holdings, Inc. | Method for producing liposomes by two-stage emulsification method using outer aqueous phase containing specific dispersing agent, method for producing liposome dispersion or dry powder thereof using the method for producing liposomes, and liposome dispersion or dry powder thereof produced thereby |
CA2766907A1 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
AR077757A1 (es) | 2009-07-15 | 2011-09-21 | Novartis Ag | Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion |
WO2011007359A2 (en) * | 2009-07-16 | 2011-01-20 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope -based anti-infective vaccines |
WO2011012316A2 (de) | 2009-07-31 | 2011-02-03 | Ludwig-Maximilians-Universität | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
JP5988492B2 (ja) | 2009-09-02 | 2016-09-07 | ノバルティス アーゲー | Tlr活性モジュレーターを含む免疫原性組成物 |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
CA2816925C (en) | 2009-11-04 | 2023-01-10 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
US20110112353A1 (en) | 2009-11-09 | 2011-05-12 | Circulite, Inc. | Bifurcated outflow cannulae |
ES2713852T3 (es) | 2009-12-01 | 2019-05-24 | Translate Bio Inc | Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas |
DK3112467T3 (da) | 2009-12-07 | 2018-04-23 | Univ Pennsylvania | Rna-præparater omfattende oprenset modificeret rna til omprogrammering af celler |
WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
WO2011075656A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
PT2525815E (pt) | 2010-01-24 | 2015-03-05 | Novartis Ag | Micropartículas de polímero biodegradável irradiadas |
US20130195961A1 (en) | 2010-03-09 | 2013-08-01 | Kejian Yang | Novel mucosal vaccination approach for herpes simplex virus type-2 |
EP2556151A1 (en) | 2010-04-07 | 2013-02-13 | Novartis AG | Method for generating a parvovirus b19 virus-like particle |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
HRP20221522T1 (hr) | 2010-07-06 | 2023-02-17 | Glaxosmithkline Biologicals S.A. | Čestice za dostavljanje nalik virionu za samo-replicirajuće rna molekule |
CN108042799A (zh) | 2010-07-06 | 2018-05-18 | 诺华股份有限公司 | 阳离子水包油乳液 |
LT3243526T (lt) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Rnr pristatymas, skirtas keleto imuninio atsako paleidimui |
EP3153578A1 (en) | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
US8898852B2 (en) | 2010-08-04 | 2014-12-02 | Honeywell International Inc. | Air burst to clear detection window |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SI3970742T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Pegilirani liposomi za dostavo RNA, ki kodira imunogen |
AU2011295938B2 (en) | 2010-08-31 | 2016-01-14 | Glaxosmithkline Biologicals S.A. | Lipids suitable for liposomal delivery of protein-coding RNA |
ES2923634T3 (es) | 2010-08-31 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Liposomas pequeños para la administración de ARN que codifica para inmunógeno |
EP2614072A4 (en) | 2010-09-09 | 2014-03-19 | Univ Virginia Commonwealth | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
AR083548A1 (es) | 2010-10-25 | 2013-03-06 | Stepan Co | Composiciones de amonio cuaternario, betaina, o sulfobetainas |
EP4144368A1 (en) | 2011-01-26 | 2023-03-08 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
ES2782119T3 (es) | 2011-05-13 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
CN103687957A (zh) | 2011-05-17 | 2014-03-26 | 现代治疗公司 | 工程化核酸及其用于非人类脊椎动物的方法 |
CA2838063C (en) | 2011-06-08 | 2023-07-11 | Shire Human Genetic Therapies, Inc. | Cleavable lipids |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
ES2657547T3 (es) | 2011-07-06 | 2018-03-05 | Glaxosmithkline Biologicals Sa | Emulsiones aceite en agua que contienen ácidos nucleicos |
ES2861428T3 (es) | 2011-07-06 | 2021-10-06 | Glaxosmithkline Biologicals Sa | Liposomas que presentan una relación N:P útil para suministro de moléculas de ARN |
EP3456316A1 (en) | 2011-07-06 | 2019-03-20 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
DK2750707T3 (da) | 2011-08-31 | 2019-02-11 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til levering af immunogen-kodende rna |
EP3384938A1 (en) | 2011-09-12 | 2018-10-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG10201602654SA (en) | 2011-10-03 | 2016-05-30 | Moderna Therapeutics Inc | Modified nucleosides,nucleotides,and nucleic acids,and uses thereof |
RU2014118727A (ru) | 2011-10-11 | 2015-11-20 | Новартис Аг | Рекомбинантные самореплицирующиеся полицистронные молекулы рнк |
EP2766385A2 (en) | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
US20140378538A1 (en) | 2011-12-14 | 2014-12-25 | Moderma Therapeutics, Inc. | Methods of responding to a biothreat |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
CA2859691A1 (en) | 2011-12-21 | 2013-06-27 | Moderna Therapeutics, Inc. | Methods of increasing the viability or longevity of an organ or organ explant |
JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
JP2015518705A (ja) | 2012-04-02 | 2015-07-06 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
AU2014204826A1 (en) | 2013-01-10 | 2015-07-09 | Seqirus UK Limited | Influenza virus immunogenic compositions and uses thereof |
US9504747B2 (en) | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
PL3083556T3 (pl) | 2013-12-19 | 2020-06-29 | Novartis Ag | Lipidy i kompozycje lipidowe dla dostarczania środków czynnych |
HUE057613T2 (hu) | 2015-09-17 | 2022-05-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
IL286515B2 (en) | 2015-10-28 | 2024-02-01 | Acuitas Therapeutics Inc | Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids |
MA46756A (fr) | 2016-11-10 | 2019-09-18 | Translate Bio Inc | Formulation de nanoparticules lipidiques à base de glace améliorée pour l'administration de l'arnm |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
WO2021038508A1 (en) | 2019-08-30 | 2021-03-04 | Glaxosmithkline Biologicals Sa | Jet mixing lipid nanoparticle manufacturing process |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
-
2011
- 2011-07-06 SI SI201130919A patent/SI2591114T1/sl unknown
- 2011-07-06 CA CA2804492A patent/CA2804492A1/en active Pending
- 2011-07-06 HU HUE11736497A patent/HUE029284T2/en unknown
- 2011-07-06 DK DK11736497.6T patent/DK2591114T3/da active
- 2011-07-06 CA CA3169291A patent/CA3169291A1/en active Pending
- 2011-07-06 JP JP2013518811A patent/JP5940064B2/ja active Active
- 2011-07-06 ES ES11736497.6T patent/ES2586580T3/es active Active
- 2011-07-06 EP EP11736497.6A patent/EP2591114B1/en not_active Revoked
- 2011-07-06 US US13/808,153 patent/US10487332B2/en active Active
- 2011-07-06 PL PL11736497T patent/PL2591114T3/pl unknown
- 2011-07-06 PT PT117364976T patent/PT2591114T/pt unknown
- 2011-07-06 WO PCT/US2011/043096 patent/WO2012006369A2/en active Application Filing
-
2016
- 2016-07-06 HR HRP20160805TT patent/HRP20160805T1/hr unknown
- 2016-07-19 CY CY20161100707T patent/CY1117819T1/el unknown
-
2019
- 2019-10-18 US US16/656,929 patent/US11655475B2/en active Active
-
2021
- 2021-10-27 US US17/512,258 patent/US11913001B2/en active Active
-
2022
- 2022-12-13 US US18/065,267 patent/US11851660B2/en active Active
- 2022-12-13 US US18/080,150 patent/US11891608B2/en active Active
- 2022-12-13 US US18/065,243 patent/US11773395B1/en active Active
- 2022-12-13 US US18/065,230 patent/US11739334B2/en active Active
- 2022-12-13 US US18/080,164 patent/US11905514B2/en active Active
- 2022-12-13 US US18/065,256 patent/US11845925B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HRP20160805T1 (hr) | 2016-08-12 |
US20230113210A1 (en) | 2023-04-13 |
WO2012006369A2 (en) | 2012-01-12 |
US11773395B1 (en) | 2023-10-03 |
WO2012006369A3 (en) | 2012-08-23 |
US20220056449A1 (en) | 2022-02-24 |
US11845925B2 (en) | 2023-12-19 |
EP2591114B1 (en) | 2016-06-08 |
JP2013530245A (ja) | 2013-07-25 |
US11913001B2 (en) | 2024-02-27 |
EP2591114A2 (en) | 2013-05-15 |
CA3169291A1 (en) | 2012-01-12 |
US11655475B2 (en) | 2023-05-23 |
US20230112809A1 (en) | 2023-04-13 |
CA2804492A1 (en) | 2012-01-12 |
CY1117819T1 (el) | 2017-05-17 |
SI2591114T1 (sl) | 2016-10-28 |
PT2591114T (pt) | 2016-08-02 |
PL2591114T3 (pl) | 2017-08-31 |
US20200048636A1 (en) | 2020-02-13 |
US11739334B2 (en) | 2023-08-29 |
US11891608B2 (en) | 2024-02-06 |
JP5940064B2 (ja) | 2016-06-29 |
US20230123931A1 (en) | 2023-04-20 |
US20130149375A1 (en) | 2013-06-13 |
HUE029284T2 (en) | 2017-02-28 |
US20230111669A1 (en) | 2023-04-13 |
ES2586580T3 (es) | 2016-10-17 |
US20230136704A1 (en) | 2023-05-04 |
US11851660B2 (en) | 2023-12-26 |
US10487332B2 (en) | 2019-11-26 |
US11905514B2 (en) | 2024-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11845925B2 (en) | Immunisation of large mammals with low doses of RNA | |
US11759475B2 (en) | Delivery of RNA to trigger multiple immune pathways | |
WO2012006372A1 (en) | Delivery of rna to different cell types |